If you have a gastroenteropancreatic neuroendocrine tumor (a GEP-NET) and you are exploring PRRT (peptide receptor radionuclide therapy) with lutetium Lu-177 dotatate in India, your first step is an eligibility evaluation. This is the appointment where a nuclear-medicine team reviews your case and decides whether lutetium Lu-177 dotatate (sold under the brand name Lutathera) is right for you. The Neuroendocrine Tumor Research Foundation explains what PRRT involves for patients new to the concept. This article covers more details: what happens at the screening appointment, what documents to bring, and how to prepare before you leave home.
What Does a PRRT Eligibility Evaluation Check?
The evaluation has two main goals. First, it confirms that your tumor cells have enough somatostatin receptors. These are surface proteins on NET cells that lutetium Lu-177 dotatate targets. When receptor expression is strong, the drug can find and irradiate your tumor cells directly. Second, it checks that your kidneys, bone marrow, and liver can safely handle four cycles of targeted radiation therapy.
Neither check is a formality. If receptor expression is too low, the drug has nothing to attach to. If organ function falls below a safe threshold, the treatment risk outweighs the benefit. The theranostics team will be direct with you about both findings, including when the news is not favorable.
To understand why somatostatin receptor targeting is central to this therapy, read our guide on how Lu-177 DOTATATE works and why receptor expression determines eligibility.
Step by Step: What Happens at Your First PRRT Consultation in India
A PRRT eligibility appointment in India usually takes one to three days, depending on whether new scans are needed. Here is what each stage involves:
- Medical records review. The team reviews your pathology reports, prior scan reports, and treatment history. This often happens the day you arrive, or even before your trip if you send records in advance.
- Ga-68 DOTATATE-PET/CT review or new scan. This is the key test. If your existing PET scan is recent, the team reviews it. If it is outdated or incomplete, they may arrange a fresh scan at the centre.
- Blood tests. A same-day panel checks kidney function, liver function, and bone marrow reserve. Results are usually back within a few hours.
- Face-to-face or video consultation. The nuclear-medicine physician meets with you and your caregiver (if present) to review your results and answer your questions.
- Treatment planning discussion. If you are eligible, the team outlines the cycle schedule, what to expect at each infusion, and any preparatory steps before your first cycle begins.
- Informed consent. If you decide to proceed, you will sign consent forms covering the therapy, its expected effects, and its possible side effects.
The Ga-68 DOTATATE-PET/CT Scan: Why It Matters
The gallium-68 DOTATATE-PET/CT scan (sometimes called a DOTATATE-PET or somatostatin receptor imaging) shows whether your tumor cells express somatostatin receptors and how strongly. The scan uses a small radioactive tracer - gallium-68 attached to DOTATATE - that binds to somatostatin receptors on tumor cells. Where the tracer concentrates, the scanner records a bright spot. The brighter your tumors appear relative to normal liver tissue, the higher your receptor expression and the more likely lutetium Lu-177 dotatate will reach and affect them.
The FDA approved lutetium Lu-177 dotatate in January 2018 specifically for adults with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors. Receptor positivity on imaging is required for treatment.
If you already have a Ga-68 DOTATATE-PET scan from your home country, bring the DICOM image files on a USB drive or disc, as well as the written report. The Indian centre needs to review the actual images, not just the summary text. Most centres prefer a scan no more than 6 to 12 months old. If yours is older, the team may recommend a fresh scan before confirming eligibility.
Blood Tests and Organ Function: What the Team Will Check
Your lab results tell the team whether your body can safely tolerate PRRT. The key panels include:
- Kidney function - serum creatinine and estimated glomerular filtration rate (eGFR). The kidneys filter lutetium from the bloodstream and take the most direct radiation load. Amino acids given during each infusion help protect them, but your baseline kidney function still matters before treatment begins.
- Bone marrow reserve - a full blood count covering hemoglobin, white blood cells, and platelets. Lutetium Lu-177 dotatate can suppress bone marrow activity over the course of treatment, so the team needs to know where you are starting from.
- Liver function - bilirubin, ALT, and AST. If you have liver metastases, the team will look closely at these numbers. Significant liver impairment changes the risk-benefit calculation for treatment.
If liver metastases are present, eligibility depends on more than a single blood test value. Our article on eligibility for Lu-177 DOTATATE when you have hepatic disease covers what the team considers in detail, including what liver replacement percentage typically affects the decision.
What to Bring to Your PRRT Eligibility Appointment
Arriving with the right documents can shorten the evaluation by a full day and reduce the chance of repeat tests. Bring all of the following:
- All pathology reports, including your biopsy report, Ki-67 index result, and any surgical specimen reports. Tumor grade (whether grade 1, 2, or 3) is central to eligibility.
- All imaging on disc or USB drive. This means the Ga-68 DOTATATE-PET/CT DICOM files, plus any CT, MRI, or ultrasound scans from the past 12 months. Bring both the images and the reports.
- Recent blood test results, ideally within the past four to six weeks. If you do not have current results, the centre will run them on arrival - but having a baseline from home helps the team track changes over time.
- A full medication list with the exact name, dose, and frequency of your somatostatin analogue (such as octreotide or lanreotide), plus all other prescribed drugs, vitamins, and supplements you take regularly.
- A written treatment summary from your home oncologist or specialist, covering your diagnosis, current disease stage, and what treatments you have received so far.
- Your oncologist's referral letter, if one is available. It is not always required, but it helps the team understand your clinical context quickly.
- A written list of your questions. The consultation moves quickly, and it is easy to forget things in the moment. Write them down before you travel.
Many patients traveling from the GCC, Africa, or South Asia find the weeks before an international medical trip stressful. Sleep disruption and pre-appointment anxiety are common. Talk to your doctor if you need support during this time.
Should You Send Your Records Before You Travel?
Yes, wherever possible. Sending your key documents ahead of your visit allows the team to identify gaps before you fly. For example, if your Ga-68 DOTATATE-PET scan is more than a year old, you can arrange a fresh one at a local centre before traveling or plan to have one done on arrival in India. Knowing this in advance prevents surprises and wasted days once you are there.
Before booking flights and accommodation, you can speak with the Art of Healing Cancer nuclear-medicine team for a remote review of your scans and pathology. This preliminary check can tell you whether your current imaging is recent enough, whether your tumor grade falls within the eligible range, and whether making the trip is likely to result in a confirmed eligibility decision before you commit to travel.
Who Is Likely to Be Eligible for Lu-177 DOTATATE?
The NETTER-1 trial (a large phase 3 study of lutetium Lu-177 dotatate in patients with midgut NETs that had progressed on high-dose somatostatin analogues) provides the main evidence base. The published results showed a hazard ratio of 0.18 for disease progression or death in patients treated with lutetium Lu-177 dotatate compared with those who remained on high-dose octreotide LAR alone. The risk of disease progression was markedly lower in the treatment group.
Criteria from that trial and from clinical practice since approval help identify who typically qualifies:
- Confirmed GEP-NET with somatostatin receptor-positive disease on Ga-68 DOTATATE-PET/CT
- Well-differentiated tumor - typically grade 1 or grade 2, Ki-67 below 20 percent
- Evidence of disease progression, not just stable disease over many years
- Adequate kidney function, bone marrow reserve, and liver function at baseline
- Overall performance status that supports completing up to four treatment cycles
Grade 3 NETs and poorly differentiated neuroendocrine carcinomas generally have lower somatostatin receptor expression and are usually not eligible, though the team will always look at the full clinical picture rather than a single number. For patients who have been on somatostatin analogues for some time and are wondering when to switch to PRRT, our article on when to switch from somatostatin analogues to Lu-177 DOTATATE covers the evidence and decision points in detail.
What If You Are Not Eligible?
Not every patient who travels for a PRRT screening will qualify. This is important to understand before you book flights. If your Ga-68 DOTATATE-PET scan shows low receptor expression, or if kidney or bone marrow function falls below the safe threshold, the team will tell you clearly and explain what alternatives may be worth discussing with your oncologist. These might include other systemic therapies, a clinical trial, or a plan to revisit eligibility later if your organ function improves.
A remote eligibility review before you travel can reduce the risk of an unnecessary trip. The Lutetium Therapy contact form allows you to send your DOTATATE-PET reports and pathology for a preliminary review. If lutetium Lu-177 dotatate is not a fit for your case, the team can also discuss what alternatives may be worth raising with your home oncologist.
How Long Will the Evaluation Take?
Plan for two to three days in India for the eligibility evaluation. On the first day, the team reviews your documents and may run fresh blood tests. On the second day, you meet the physician for the formal consultation. If a new Ga-68 DOTATATE-PET scan is needed, add one more day for the scan and reporting.
If you are confirmed eligible and ready to proceed, the first cycle of lutetium Lu-177 dotatate may be scheduled for the same trip or for a return visit, depending on the centre's schedule and your travel plans. Most patients complete four cycles spaced roughly eight weeks apart - meaning three to four return trips if traveling from abroad. For a full breakdown of what this costs in India compared to the US, UK, and UAE, see our cost comparison for international NET patients seeking PRRT in India.
When to Talk to Your Doctor
Talk to your oncologist or gastroenterologist before you travel for a PRRT evaluation if your disease has changed recently, if you have started or stopped a somatostatin analogue, if your kidney function has declined since your last check, or if your most recent imaging is more than six months old. These updates directly affect how the eligibility team reads your case and what decisions they can make at the appointment.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Do I need a Ga-68 DOTATATE-PET scan before I travel to India for PRRT?
It helps to have one, but it is not always required before you travel. Many centres in India will review an existing scan if it is recent - usually within 6 to 12 months. If your scan is older, or if you have not had one yet, the centre can arrange it on arrival. Sending your existing imaging ahead of time allows the team to tell you in advance whether a new scan is needed, which can save you a day or more once you are there.
How long does the PRRT eligibility evaluation take in India?
Most patients should plan for two to three days. This covers the document review, any same-day blood tests, and the formal consultation with the nuclear-medicine physician. If a new Ga-68 DOTATATE-PET scan is needed because your existing scan is outdated or incomplete, add one more day for the scan itself and for the results to be reported.
Can I have Lu-177 DOTATATE treatment if I have liver metastases?
Liver metastases alone do not rule out PRRT. What matters is how much of the liver is replaced by tumor and how well the remaining liver is functioning. If liver function tests - bilirubin, ALT, and AST - are within acceptable limits, many patients with liver metastases may be eligible. The eligibility team will look at your imaging and blood results together to assess this. Ask about this specifically at your consultation if liver involvement is part of your picture.
What should I do with my octreotide or lanreotide before PRRT?
This is an important question to raise with your treating physician before you travel. Somatostatin analogues can compete with lutetium Lu-177 dotatate for the same receptors if given too close to the infusion. Your team will give you specific guidance on timing - do not stop or change your dose without their instruction, as stopping abruptly can cause a rebound of symptoms in patients with carcinoid syndrome.
What tumor grade qualifies for Lu-177 DOTATATE?
The treatment is generally suitable for well-differentiated GEP-NETs - grade 1 (Ki-67 below 3 percent) and grade 2 (Ki-67 between 3 and 20 percent). Grade 3 tumors and poorly differentiated neuroendocrine carcinomas typically have lower somatostatin receptor expression and are usually not eligible, though each case is reviewed individually. If your Ki-67 is close to the 20 percent boundary, bring your full pathology report so the team can assess the whole picture.
What if I am not eligible for PRRT - what happens next?
If eligibility cannot be confirmed - because of low receptor expression on the scan, inadequate organ function, or another factor - the team should explain what other options may suit your situation. These might include continuing or switching somatostatin analogues, targeted therapies that may be relevant for your NET type, or clinical trials. A second opinion from a different theranostics centre may also be worth considering, as eligibility decisions can sometimes differ when a fresh team reviews the same scans.